Skip to content

Prevention of hyperalgesia after laparoscopic total hysterectomy with esmketamine and parecoxib

Prevention of hyperalgesia after laparoscopic total hysterectomy with esmketamine and parecoxib

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037996
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic hysterectomy

Interventions

Group C:Norm saline
Group EP:Esketamine combined with parecoxib

Sponsors

Wuxi Xishan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The patients who underwent laparoscopic hysterectomy were selected; 2. Patients aged 18-65 years old; 3. Patients with body mass index of 15-30 kg / m2; 4. Patients with preoperative American Society of anesthesiologists (ASA) grade I ~ II.

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart and lung diseases; 2. Patients with liver and kidney dysfunction; 3. Patients with chronic pain history; 4. Patients with mental illness; 5. Patients with a history of gastrointestinal disease (peptic ulcer disease, Crohn's disease or ulcerative colitis).

Design outcomes

Primary

MeasureTime frame
Mechanical hyperalgesia threshold;

Secondary

MeasureTime frame
Oxycodone consumption for first 48 h postoperatively;NRS scores at different time after surgery;Postoperative adverse effects;

Countries

China

Contacts

Public ContactQingren Liu

Wuxi Xishan People's Hospital

Liuqr5250@163.com+86 13601510412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026